Should I buy GSK stock in 2025?

Why trust HelloSafe ?

At HelloSafe, our expert has been tracking GSK's performance for over three years. Every month, over a million users in the UK trust us to decipher market trends and identify the best investment opportunities. Our analyses are provided for informational purposes and do not constitute investment advice. In accordance with our ethical charter, we have never been, and will never be, compensated by GSK.

What is GSK?

GSK stock price

The price of GSK stock is rising this week. As of the latest update, GSK trades at $38.59, reflecting a 0.91% decline over the past 24 hours but a 0.80% gain this week. Market capitalisation stands at $78.05 billion, supported by an average three-month daily volume of 5.6 million shares. The stock’s current P/E ratio is 18.46, dividend yield is 4.17%, and the beta is 0.27, indicating relatively stable price movement. Investors should note that GSK shows a history of steady performance with attractive income potential and moderate volatility.

Our full analysis on GSK stock

Having conducted an integrated review of GSK’s latest financial results alongside the stock’s performance trajectory over the past three years, our analysis harnesses a broad spectrum of insights—including financial indicators, technical momentum, sector trends, and peer benchmarks—curated through our proprietary algorithms. By integrating multiple streams of verified data, we provide an expert-level assessment designed to uncover both current value and future potential. So, why might GSK stock once again become a strategic entry point into the pharmaceutical and healthcare innovation sector in 2025?

Recent performance and market context

GSK shares have displayed a constructive trajectory, with the current price at $38.59, representing a gain of 0.80% over the past week and 13.65% over six months. Daily trading activity remains substantial, averaging 5.6 million shares, while the overall market capitalisation stands at $78.05 billion. This solid performance is further supported by resilient fundamentals and the company’s continued expansion within both its core UK base and strategic global markets. Notably, recent milestones—such as the FDA approval for the Benlysta autoinjector and the high-profile relocation of the corporate headquarters to central London—have reinforced investor confidence and enhanced GSK’s standing in the eyes of both the domestic and international community. The backdrop of stable growth in the broader pharmaceutical sector, fuelled by healthcare innovation, demographic trends, and rising demand for speciality medicines, continues to favour blue-chip players like GSK in the UK market.

Technical analysis

The technical signals for GSK are leaning bullish, with clear indications of underlying market support. The RSI sits at 48.28, reflecting a neutral but stable position, while the MACD (-0.17) points toward an emerging buy signal. Importantly, GSK’s share price is trading around key moving averages: the 50-day ($38.70), 100-day ($37.86), and 200-day ($36.60) all provide strong reinforcement, suggesting favourable short- and medium-term momentum. Recent trading has positioned the stock just above major support at $37.68, with overhead resistance at $39.17. Should the price break through resistance, momentum traders would likely be encouraged by these technical cues. The steady support across moving averages and key technical levels adds confidence that the current phase presents an advantageous entry for investors seeking a blend of stability and upside.

Fundamental analysis

GSK distinguishes itself with robust financial metrics and a clear growth narrative. The company delivered £7.52 billion in Q1 2025 revenue, up 4% on a constant currency basis, outperforming analyst expectations for both topline and core EPS ($1.13 vs. expected $1.08). With a P/E ratio of 18.46, the stock is attractively valued relative to high-growth peers, and a generous dividend yield of 4.17% offers both income and reassurance. Key fundamental strengths include:

• Consistent revenue and operating profit growth, underpinned by blockbuster speciality medicines and a well-diversified vaccine portfolio.
• A strategic focus on R&D and partnerships, exemplified by mRNA vaccine collaboration with CureVac and deep investments in respiratory and HIV therapies.
• Powerful brand equity, with a global footprint and strong UK market recognition, reinforcing GSK’s leadership in pharmaceutical innovation.

These structural strengths—matched by prudent financial management and shareholder-friendly policies—construct a compelling investment thesis grounded in both growth and resilience.

Volume and liquidity

GSK continues to benefit from exceptionally deep liquidity, with an average daily volume of 5.6 million shares supporting robust market activity and efficient price discovery. The combination of a large float, stable trading flows, and index membership positions GSK as an attractive holding not only for individual investors but also for institutional funds and ETFs. This liquidity enables responsive trading and portfolio rebalancing—even in volatile periods—while the stock’s relatively low beta of 0.27 underscores its defensive qualities in turbulent market cycles.

Catalysts and positive outlook

Several forward-looking catalysts highlight the potential for renewed upside in GSK:

• Specialty medicine growth: Segment revenue surged 17% in Q1, driven by new launches and expansion into high-growth therapeutic categories.
• Rich innovation pipeline: Ongoing trials in respiratory, HIV, oncology, and immunology position GSK for successive future approvals.
• Strategic M&A and partnerships: Collaborations and targeted acquisitions, especially in promising biotechnology fields, continue to expand market reach and access to disruptive technologies.
• Shareholder rewards: The ongoing £2 billion share buyback programme and strong quarterly dividend payments underscore the management’s commitment to value creation.
• Favourable analyst consensus: The prevailing “Strong Buy” rating, with consensus price targets above current levels, reflects strong market conviction in the stock’s outlook.

Layered on top of these factors, the company’s transition to a newly central London headquarters demonstrates both ambition and an ability to attract global talent, fostering an innovative work environment in a sector where proximity to the brightest minds is essential.

Investment strategies

GSK offers several compelling strategies for investors across different time horizons:

• Short-term: Investors can take advantage of the current support near technical lows and potential resistance breakouts, supported by robust trading volume and positive news flow.
• Medium-term: Momentum builds around product launches, regulatory milestones, and quarterly results, offering potential for appreciation as these events unfold.
• Long-term: The company’s leadership in vaccines, commitment to speciality medicines, R&D expansion, and consistent dividend growth support a strategy of steady accumulation and compounding returns.

Current technical levels are especially attractive for incremental entry, and with upcoming catalysts such as trial results or new approvals on the horizon, buying ahead of these may align with higher return potential. The company’s proven ability to navigate sector headwinds and adapt to global health challenges further strengthens the investment case for the medium to long term.

Is it the right time to buy GSK?

In summary, GSK stands out as a high-quality, fundamentally strong stock, exceptionally well placed to benefit from sector shifts towards speciality medicines and vaccine innovation. The blend of steady growth, ambitious R&D, prudent capital allocation, and a shareholder-focused approach offers a compelling case for renewed interest. Technical signals suggest the stock may be entering a new bullish phase, while its low volatility, attractive yield, and global leadership make it a solid anchor for diversified portfolios. For investors seeking both stability and sustainable growth from a British-listed pharmaceutical leader, GSK seems to represent an excellent opportunity at this juncture—one with both defensive merit and future upside as the healthcare sector evolves.

How to buy GSK stock

Buying GSK shares online is both simple and secure for UK investors using an FCA-regulated broker. There are two main ways to invest: spot buying, where you directly own GSK shares, and CFD trading, which lets you speculate on price changes using leverage. Both approaches are accessible via most modern trading platforms. To help you find the best solution, you’ll find a detailed broker comparison further down the page.

Spot buying

With cash (spot) buying, you become a direct shareholder of GSK. Most UK brokers charge a low, fixed commission—typically £5–£10 per order.

Gain scenario

If the GSK share price is $38.59, you can buy around 25 shares with a $1,000 stake, including a brokerage fee of around $5.

If the share price rises by 10%, your shares are now worth $1,100.

Result: +$100 gross gain, i.e. +10% on your investment.

Trading via CFD

CFD (Contract for Difference) trading allows you to speculate on GSK’s price movements with leverage and without owning the underlying shares. Costs mainly include the spread and overnight financing if you hold leveraged positions beyond one day.

Gain scenario:

You open a CFD position on GSK shares, with 5x leverage.

This gives you a market exposure of $5,000.

If the stock rises by 8%, your position gains 8% × 5 = 40%.

Result: +$400 gain, on a bet of $1,000 (excluding fees).

Final advice

Before buying GSK stock, always compare brokers’ commission, spreads, and available features to find the best match for your goals. Your final choice should reflect your own investment strategy—whether you favour simple shareholding or more active trading. You can consult a comprehensive broker comparison further down this page.

Our 7 tips for buying GSK stock

The latest news about GSK

GSK’s stock price achieved a one-week gain of 0.80%, reflecting growing investor confidence after Q1 results. Trading on both the London and New York Stock Exchanges, GSK ended the week at $38.59 USD, buoyed by robust operating performance and upbeat analyst sentiment, with a six-month increase exceeding 13%.

GSK outperformed expectations in Q1 2025, posting core EPS of $1.13 versus a forecasted $1.08. Revenue reached £7.52 billion in the quarter, up 4% at constant currency, and operational profit rose 5%. This solid showing underscores GSK’s ability to consistently deliver results ahead of expectations, pleasing both investors and market commentators in the UK.

The company confirmed further share buybacks and a planned full-year dividend of 64p for 2025. GSK has repurchased shares worth £273 million within a £2 billion programme, reinforcing its commitment to shareholder returns. The announced quarterly dividends provide additional reassurance to investors seeking income, supporting the stock’s appeal in the UK market.

Strategic innovation continues as GSK secures FDA approval for the Benlysta autoinjector and accelerates its vaccine pipeline. This development not only broadens GSK’s specialised medicines portfolio but also complements ongoing partnerships in HIV therapies and mRNA vaccine innovation, maintaining the company’s leadership in advanced therapeutics and public health.

GSK’s London pivot is marked by the move to a new headquarters in Central London. Relocating from Brentford to 79 New Oxford Street highlights GSK’s persistent commitment to the UK market and strategic proximity to industry partners, regulators, and global investors, further elevating its profile within Britain’s rapidly evolving life sciences sector.

FAQ

P. Laurore

Finance expert

Co-founder of HelloSafe and holder of a Master's degree in finance, Pauline has recognised expertise in personal finance, which she uses to help users better understand and optimise their financial choices. At HelloSafe, Pauline plays a key role in designing clear, educational content on savings, investments and personal finance. Passionate about financial education, Pauline strives, with every piece of content she oversees, to provide reliable, transparent and unbiased information for independent and informed financial management. To this end, she has tested over 100 trading platforms to help internet users make the right choices.